Metropolitan Life Insurance CO Icosavax, Inc. Transaction History

Metropolitan Life Insurance CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 30, 2023	SELL	$2.32 - $10.97 $693 - $3,280	-299 Reduced 16.65%	1,497 $11,000
Q4 2022 Feb 15, 2023	BUY	$2.32 - $10.97 $3,473 - $16,422	1,497 New	1,497 $11,000
Q2 2022 Aug 11, 2022	SELL	$5.7 - $10.33 $10,237 - $18,552	-1,796 Closed	0 $0
Q1 2022 Jun 20, 2023	BUY	$4.41 - $22.5 $1,318 - $6,727	299 Added 19.97%	1,796 $12,000
Q1 2022 Mar 30, 2023	SELL	$4.41 - $22.5 $9,618 - $49,072	-2,181 Reduced 54.84%	1,796 $12,000
Q1 2022 May 12, 2022	SELL	$4.41 - $22.5 $9,618 - $49,072	-2,181 Reduced 54.84%	1,796 $13,000
Q4 2021 Jun 21, 2023	BUY	$21.07 - $34.98 $52,253 - $86,750	2,480 Added 165.66%	3,977 $90,000
Q3 2021 Jun 21, 2023	BUY	$24.85 - $40.25 $61,628 - $99,820	2,480 Added 165.66%	3,977 $117,000
Q3 2021 Mar 30, 2023	BUY	$24.85 - $40.25 $61,628 - $99,820	2,480 Added 165.66%	3,977 $117,000
Q3 2021 Nov 15, 2021	BUY	$24.85 - $40.25 $98,828 - $160,074	3,977 New	3,977 $118,000

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.